In this context, the American Diabetes Association (ADA)/the European Association for the Study of Diabetes (EASD) recommended the use of GLP-1 RA as the first-line injectable in such T2DM subjects who do not achieve HbA1c targets with one or more oral glucose-lowering agents. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.